Atrium Therapeutics, Inc. (RNA)
RNA Stock Price Chart
Explore Atrium Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze RNA price movements and trends.
RNA Company Profile
Discover essential business fundamentals and corporate details for Atrium Therapeutics, Inc. (RNA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Feb 2026
Employees
511.00
CEO
Kathleen Gallagher
Description
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
RNA Financial Timeline
Browse a chronological timeline of Atrium Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
RNA Stock Performance
Access detailed RNA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
